UOC
BIIB icon

UBS O'Connor’s Biogen BIIB Stock Holding History

UBS O'Connor’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$539K – 557
2024
Q1 		$539K Sell
2,500
-2,379
-49% -$557K 0.02% 328
2023
Q4 		$1.26M Sell
4,879
-17,121
-78% -$4.21M 0.04% 242
2023
Q3 		$5.65M Buy
+22,000
New +$5.88M 0.1% 105
2023
Q2 		– Sell
-8,610
Closed -$2.39M – 591
2023
Q1 		$2.39M Buy
8,610
+1,545
+22% +$427K 0.06% 279
2022
Q4 		$1.96M Buy
7,065
+1,115
+19% +$315K 0.04% 468
2022
Q3 		$1.59M Buy
+5,950
New +$1.26M 0.02% 681
2013
Q3 		– Sell
-36,000
Closed -$7.75M – 433
2013
Q2 		$7.75M Buy
+36,000
New +$7.69M 0.15% 192

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS O'Connor's BIIB Position: Q2 2024 in Review

UBS O'Connor sold out of Biogen (BIIB) in Q2 2024, closing a stake of 2,500 shares — an estimated $539K sold.

UBS O'Connor first reported a position in BIIB in Q2 2013 and held it in 7 quarters. The position peaked at $7.75M in Q2 2013. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

  • UBS O'Connor reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 2,500 Biogen shares in Q2 2024, an estimated $539K.
  • UBS O'Connor first reported a position in Biogen in Q2 2013 and held it in 7 quarters.
  • UBS O'Connor's Biogen position peaked at $7.75M in Q2 2013.
  • 944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.